• Featured Product
  • KD/KO Validated

Alpha Parvin/Actopaxin Polyclonal antibody

Alpha Parvin/Actopaxin Polyclonal Antibody for IHC, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC,ELISA

Conjugate

Unconjugated

Cat no : 11202-1-AP

Synonyms

Actopaxin, Alpha parvin, CH ILKBP, MXRA2, PARVA, parvin, alpha, α-Parvin



Tested Applications

Positive WB detected inhuman liver tissue, Jurkat cells, HeLa cells, human kidney tissue
Positive IHC detected inhuman prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:20-1:200
Sample-dependent, check data in validation data gallery

Published Applications

IHCSee 1 publications below

Product Information

11202-1-AP targets Alpha Parvin/Actopaxin in WB, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Alpha Parvin/Actopaxin fusion protein Ag1694
Full Name parvin, alpha
Calculated molecular weight 42 kDa
Observed molecular weight 42-45 kDa
GenBank accession numberBC016713
Gene symbol PARVA
Gene ID (NCBI) 55742
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Protocols

Product Specific Protocols
WB protocol for Alpha Parvin/Actopaxin antibody 11202-1-APDownload protocol
IHC protocol for Alpha Parvin/Actopaxin antibody 11202-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

Transl Androl Urol

Downregulation of PARVA promotes metastasis by modulating integrin-linked kinase activity and regulating MAPK/ERK and MLC2 signaling in prostate cancer.

Authors - Cong Huang